What is age related macular degeneration in simple terms?

Age related macular degeneration is an eye disease that damages the macula, the part of the retina used for sharp central vision. It usually affects adults over 55. The “dry” type causes slow wear-and-tear; the “wet” type causes leakage or bleeding. Peripheral vision is usually preserved.

Is age related macular degeneration serious?

Yes. AMD can take away central vision used for reading, driving, and recognizing faces. The wet form can worsen quickly without treatment. Modern injections often stabilize or improve vision, but early diagnosis and consistent follow-up matter to reduce permanent vision loss.

What are the first signs of macular degeneration?

Early signs include blurred central vision, needing more light to read, and straight lines looking wavy on an Amsler grid. Colors may seem less vivid. If new distortion or a central blind spot appears, contact an eye doctor quickly to check for wet AMD.

How is macular degeneration diagnosed?

An eye doctor makes the diagnosis by dilated eye exam and imaging. Optical coherence tomography (OCT) shows drusen, fluid, or atrophy. Fluorescein or OCT angiography may confirm abnormal blood vessels. No blood test is needed. Regular checks help catch vision-threatening changes early.

Can macular degeneration be cured or reversed?

There is no cure. Treatments can slow the disease and, in wet AMD, often stabilize or improve vision. AREDS2 vitamins lower the chance of progression in certain dry stages. New injections for geographic atrophy slow enlargement of dead retina but do not restore lost vision.

Do vitamins really help AMD?

AREDS2 vitamins help people with intermediate AMD or advanced AMD in one eye by lowering the risk of progression. They do not benefit early AMD and do not replace healthy diet or quitting smoking. Smokers should avoid beta-carotene–containing supplements due to lung cancer risk.

How often are eye injections needed for wet AMD?

Injections often start monthly for a few months, then the interval is extended based on scans and vision, commonly every 6 to 12 weeks. Some eyes need closer follow-up. Skipping visits can allow fluid and scarring to return, risking permanent vision loss.

What happens if wet AMD is not treated?

Untreated wet AMD often leads to rapid central vision loss, scarring, and a permanent blind spot. Early and sustained anti-VEGF treatment greatly improves the odds of keeping useful vision. Call your eye doctor promptly if you notice new distortion, central blur, or bleeding.

Can I do anything at home for macular degeneration?

Home steps include not smoking, eating leafy greens and fish, using an Amsler grid to check for changes, and taking AREDS2 vitamins if your doctor recommends them. Home care cannot stop wet AMD bleeding or leakage—new distortion or vision loss needs urgent medical treatment.

Does macular degeneration affect both eyes?

It often involves both eyes over time, but not always equally. One eye may remain in a dry stage while the other develops wet changes. Regular exams and self-monitoring help detect changes early in either eye so treatment can be started promptly.

How long does recovery take after an eye injection?

Most people have mild irritation or a bloodshot eye for 24 to 48 hours. Vision may be hazy for a day from the antiseptic or air bubbles. Severe pain or a big vision drop after an injection is not normal—call your eye doctor right away.

Is macular degeneration the same as dry eye or conjunctivitis?

No. AMD affects the retina and causes central blur or distortion without eye redness or discharge. Conditions like dry eye or bacterial conjunctivitis usually cause irritation, tearing, or mucus. If your eye is red and painful, an infection or keratitis may be the cause, not AMD.

Age Related Macular Degeneration

Name: Age Related Macular Degeneration
Creator: Oleksii Sologub
Published: 2020-06-23

Overview

By Oleksii Sologub, Editor-in-Chief

Self-check

Take the Amsler Grid Test online, free, in a couple of minutes.

A quick at-home screening. It does not replace a professional eye exam.

Start the test

Age related macular degeneration (AMD) is a chronic, progressive disease of the macula that causes central vision loss, typically after age 55. The nonexudative (“dry”) form ranges from early drusen to geographic atrophy; the exudative (“wet”) form features choroidal neovascularization with retinal fluid or hemorrhage. Diagnosis is clinical, supported by optical coherence tomography and angiography as needed. Treatment includes AREDS2 vitamins for appropriate stages, intravitreal anti-VEGF agents for neovascular AMD, and complement inhibitors for geographic atrophy.

Key Points

AMD damages the macula and impairs central vision; peripheral vision is usually preserved.
Smoking is the strongest modifiable risk factor; age and genetics drive baseline risk.
Intravitreal anti-VEGF therapy stabilizes or improves vision in most eyes with neovascular AMD.
AREDS2 vitamins reduce the risk of progression from intermediate to advanced AMD.
New intravitreal complement inhibitors can slow geographic atrophy enlargement but do not restore lost vision.
Urgent evaluation is warranted for new distortion, central blur, or macular hemorrhage.

Anatomy and Physiology

The macula is the central retina responsible for high-acuity and color vision. The retinal pigment epithelium (RPE) supports photoreceptors and maintains the visual cycle. Beneath the RPE lie Bruch membrane and the choriocapillaris, which supply metabolic support. AMD primarily affects the RPE–Bruch membrane–choriocapillaris complex, leading to photoreceptor dysfunction and loss.

Etiology

Age-related changes in Bruch membrane and the RPE with accumulation of extracellular deposits (drusen and basal laminar deposits).
Genetic susceptibility (e.g., variants in complement factor H [CFH] and ARMS2/HTRA1).
Environmental and systemic risks:
- Cigarette smoking (dose-dependent).
- Caucasian race, family history, increasing age.
- Cardiovascular risk factors (hypertension, hyperlipidemia), obesity, low dietary intake of lutein/zeaxanthin and omega-3-rich fish.
- Light iris color and high cumulative light exposure have been variably associated.

Pathophysiology

Nonexudative AMD: Lipid-rich drusen and RPE pigmentary changes reflect impaired outer retinal metabolism and inflammation (complement pathway activation). Progression leads to RPE and photoreceptor loss (geographic atrophy).
Exudative AMD: Pathologic upregulation of vascular endothelial growth factor (VEGF) induces choroidal neovascularization (CNV) through defects in Bruch membrane. CNV leaks or bleeds, causing intraretinal/subretinal fluid, fibrovascular pigment epithelial detachment (PED), and disciform scarring.
Disease may be bilateral and asymmetric; nonexudative AMD can convert abruptly to exudative AMD.

Epidemiology

In the United States, age related macular degeneration is the leading cause of irreversible central vision loss among older adults. Prevalence rises steeply with age and is higher in individuals of European ancestry and in smokers [1,2]. Geographic atrophy and neovascular AMD represent advanced stages with the greatest visual impact.

Classification

Early AMD: Multiple small drusen or few medium drusen without RPE changes.
Intermediate AMD: Numerous medium drusen or at least one large druse, and/or RPE pigmentary changes (AREDS/Beckman classification).
Advanced AMD:
- Geographic atrophy (GA): Well-demarcated RPE and photoreceptor loss involving or approaching the fovea.
- Neovascular (exudative) AMD: CNV with subretinal/intraretinal fluid, hemorrhage, or fibrovascular PED.

Subtypes of CNV (type 1 sub-RPE, type 2 subretinal, type 3 retinal angiomatous proliferation). Polypoidal choroidal vasculopathy (PCV) is a pachychoroid-associated variant responsive to anti-VEGF and often to adjunctive photodynamic therapy.

Symptoms and Signs

Nonexudative (early/intermediate)

Gradual central blur, difficulty reading or recognizing faces, decreased contrast sensitivity.
Metamorphopsia (distortion) may be subtle; Amsler grid can reveal wavy or missing lines.
Fundus: Drusen (yellow deposits), RPE mottling or hyper/hypopigmentation.

Geographic atrophy

Paracentral scotomas progressing toward central scotoma; glare disability and slow dark adaptation.
Fundus: Sharply demarcated areas of RPE/choriocapillaris atrophy; hypoautofluorescence on fundus autofluorescence.

Neovascular (exudative) AMD

Acute or subacute metamorphopsia, central scotoma, rapid decline in central acuity.
Fundus/OCT: Subretinal or intraretinal fluid, subretinal hyperreflective material, macular hemorrhage, fibrovascular PED.

Complications

RPE tears, especially with large or vascularized PEDs.
Massive submacular hemorrhage and disciform scarring with poor visual prognosis if untreated.
Bilateral involvement over time.
Treatment-related: Endophthalmitis, transient intraocular pressure rise, tractional events; with brolucizumab, occlusive vasculitis/retinal artery occlusion risk (rare) [3].

Diagnosis

Clinical evaluation

Best-corrected visual acuity, Amsler grid symptoms, color and contrast sensitivity as needed.
Dilated fundus examination to assess drusen, pigment changes, hemorrhage, fluid, or atrophy.

ICD-10-CM coding

Nonexudative AMD: H35.311 (right eye), H35.312 (left), H35.313 (bilateral), H35.319 (unspecified eye).
Exudative AMD: H35.321 (right eye), H35.322 (left), H35.323 (bilateral), H35.329 (unspecified eye).

Imaging and laboratory testing

Optical coherence tomography (OCT): Primary test to detect drusen morphology, RPE changes, geographic atrophy extent, and intraretinal/subretinal fluid.
OCT angiography (OCT-A): Noninvasive visualization of CNV; supportive in selected cases.
Fluorescein angiography (FA): Leakage pattern confirmation, lesion type; useful when diagnosis is uncertain or prior to PDT; CPT 92235.
Indocyanine green angiography (ICGA): Helpful for PCV detection; CPT 92240.
Fundus autofluorescence: Maps GA progression; often captured with CPT 92250.
Laboratory testing and genetic testing are not routinely indicated for AMD management [1].

CPT procedural codes

Intravitreal injection: CPT 67028.
OCT retina: CPT 92134.
Photodynamic therapy (verteporfin): CPT 67221.

Differential diagnosis

Entity	Distinguishing features
Diabetic macular edema	Diabetic retinopathy signs, microaneurysms, hard exudates; OCT cystoid edema without drusen
Central serous chorioretinopathy	Younger/middle-aged, serous neurosensory detachment, “smokestack/inkblot” on FA
Myopic CNV	High myopia, lacquer cracks, peripapillary atrophy; small juxtafoveal CNV
Pattern dystrophies	Younger onset, lipofuscin patterns, family history; slower progression
Ocular histoplasmosis syndrome	Peripapillary atrophy, “histo spots,” absence of vitritis
Macular hole/epiretinal membrane	Positive Watzke-Allen sign; ERM traction on OCT
Vitreomacular traction	Foveal distortion with posterior hyaloid adherence on OCT
Uveitic/inflammatory CNV	Inflammation signs, cells/flare; systemic disease clues

Treatment

Medical management

Nonexudative/intermediate AMD (AREDS2):
- Recommend an AREDS2 formulation to reduce progression to advanced AMD: vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg (as zinc oxide), copper 2 mg (as cupric oxide), lutein 10 mg, zeaxanthin 2 mg daily [4]. Avoid beta-carotene in current or former smokers due to lung cancer risk.
- Nutritional counseling: Diet rich in leafy greens, colorful vegetables, and fish (omega-3–rich); maintain healthy weight and blood pressure [1].
- Home monitoring: Amsler grid; consider commercial hyperacuity home monitoring for high-risk patients.
Geographic atrophy secondary to AMD:
- Pegcetacoplan intravitreal 15 mg/0.1 mL monthly or every other month slows GA growth; discuss risks including increased exudative conversion and inflammation [5].
- Avacincaptad pegol intravitreal 2 mg monthly slows GA enlargement; similar counseling on risks [6].
- These agents do not restore lost vision; shared decision-making on visit burden and benefit.
Neovascular (exudative) AMD:
- Anti-VEGF intravitreal therapy (first-line):
- Ranibizumab 0.5 mg monthly, then treat-and-extend or PRN after loading [7].
- Aflibercept 2 mg every 4 weeks for 3 injections, then typically every 8 weeks; longer intervals (q12–16 weeks) based on disease control; 8 mg formulation permits extended dosing per FDA labeling [8].
- Faricimab-svoa 6 mg every 4 weeks for 4 doses, then extend to q8–16 weeks based on activity [9].
- Brolucizumab 6 mg monthly x3, then q8–12 weeks; discuss rare risk of retinal vasculitis/occlusion and monitor closely [3].
- Bevacizumab 1.25 mg off-label is commonly used with comparable efficacy to ranibizumab in randomized trials (CATT) [10] (off-label).
- Regimens: Fixed monthly, treat-and-extend (preferred in many practices), or PRN after loading; close OCT-guided monitoring.
- Adjuncts in select cases: Verteporfin photodynamic therapy for PCV or resistant lesions (often combined with anti-VEGF) [11]. Thermal laser is rarely indicated for extrafoveal classic CNV.

Systemic medications (statins, aspirin) are not used to treat AMD; continue or adjust these solely for systemic indications. There is no proven benefit of blue-light–blocking lenses or high-dose omega-3 supplements in AMD progression [4].

Adverse event counseling (intravitreal injections): Endophthalmitis, transient IOP rise, vitreous floaters, small risk of retinal detachment or hemorrhage; postinjection red eye without pain or vision drop is common and benign.

Procedural and surgical management

Intravitreal injection delivered in-office under topical anesthesia and povidone-iodine antisepsis (CPT 67028).
Photodynamic therapy with verteporfin for select PCV lesions or nonresponders (often combination therapy) [11].
Submacular surgery, macular translocation, and radiation are not standard of care.

Special populations

Pediatric: AMD does not occur in children; consider inherited macular dystrophies in young patients with similar findings.
Pregnancy/lactation: Avoid anti-VEGF agents if possible due to theoretical fetal risk; defer therapy or use alternative timing after obstetric consultation. Data in lactation are limited; shared decision-making is essential.
Smokers: Strongly recommend cessation; avoid beta-carotene–containing supplements.
Elderly/frail: Tailor visit frequency and regimen (e.g., treat-and-extend). Anticoagulation is not a contraindication to intravitreal injection.

Prognosis

Nonexudative AMD may remain stable for years; risk of progression correlates with drusen size and pigmentary changes (AREDS risk categories) [1].
Geographic atrophy enlarges over time; central involvement leads to legal blindness for reading and face recognition. Complement inhibitors can slow, but not halt, enlargement [5,6].
Without treatment, neovascular AMD commonly causes severe central vision loss. With anti-VEGF therapy, most eyes maintain vision, and a meaningful fraction improve, especially with early detection and consistent treatment [7,10].

Prevention and Patient Counseling

Do not smoke; seek evidence-based cessation support.
Control blood pressure, lipids, and weight; exercise regularly.
Eat a diet rich in leafy greens and fish; use AREDS2 vitamins if indicated by stage.
Use an Amsler grid or home monitoring; report new distortion or central blur immediately.
Sunglasses and UV protection are reasonable; direct causal prevention evidence is limited.
Low-vision rehabilitation and assistive devices can maximize function in advanced disease.

When to Seek Immediate Care

Sudden or new wavy/distorted lines (metamorphopsia).
New central gray or black spot in your vision.
Rapid drop in central vision in one or both eyes.
New or increased eye floaters with flashes of light.
New dark red spot or bleeding seen in the eye.
Severe eye pain or sudden vision loss — call 911.

References

American Academy of Ophthalmology Preferred Practice Pattern Retina/Vitreous Panel. Age-Related Macular Degeneration PPP. AAO; 2023. https://www.aao.org/preferred-practice-pattern
National Eye Institute. Age-Related Macular Degeneration (AMD). NEI; 2024. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration
U.S. Food and Drug Administration. Beovu (brolucizumab) Prescribing Information. FDA; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration. N Engl J Med. 2013;368(20):1899-1910. doi:10.1056/NEJMoa1305240.
Liao DS, et al. Pegcetacoplan for geographic atrophy in age-related macular degeneration (OAKS/DERBY). Ophthalmology. 2023;130(10):1114-1127.
Guymer RH, et al. Avacincaptad pegol for geographic atrophy (GATHER2). Ophthalmology. 2023;130(9):1052-1063.
Rosenfeld PJ, et al. Ranibizumab for neovascular AMD (MARINA/ANCHOR). N Engl J Med. 2006–2007. doi:10.1056/NEJMoa054481; doi:10.1056/NEJMoa061259.
Regillo CD, et al. Aflibercept dosing and outcomes in nAMD; and Eylea HD label. Ophthalmology. 2012;119(12):2537-2548; FDA Label 2023.
Heier JS, et al. Faricimab in nAMD (TENAYA/LUCERNE). Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00012-2.
Martin DF, et al. Ranibizumab vs bevacizumab for neovascular AMD (CATT). N Engl J Med. 2011;364(20):1897-1908. doi:10.1056/NEJMoa1102673.
Lee WK, et al. Verteporfin PDT plus ranibizumab vs ranibizumab monotherapy for polypoidal choroidal vasculopathy (EVEREST II). Ophthalmology. 2018;125(8):1151-1161. doi:10.1016/j.ophtha.2018.03.061.

Disclaimer: This article is for informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified eye care professional about your specific condition. If you have sudden vision loss, severe eye pain, or an eye injury, seek emergency care immediately.